Board Meeting29 Jul 2026, 04:41 pm
Vivanta Industries Ltd Board Approves Unaudited Financial Results
AI Summary
Vivanta Industries Ltd announced that its Board of Directors has approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The approval also includes year-to-date figures for the period from April 1, 2026, to June 30, 2026. The board meeting also noted disclosures of interest from directors, declarations from independent directors, issuance of duplicate share certificates, business collaboration agreements with Qness Pharmaceuticals, corporate governance report, e-form DPT-3, and authorization for opening trading and demat accounts. Designated signatories were authorized to file statutory forms.
Key Highlights
- Board approved unaudited standalone and consolidated financial results for Q1 FY27.
- Year-to-date figures for April 1, 2026, to June 30, 2026, were also approved.
- Business collaboration agreements with Qness Pharmaceuticals were noted.
- Duplicate share certificates were approved for issuance.
- Designated signatories authorized for statutory filings.
Price Impact
More from VIVANTA